2025 Cancer Immunotherapy Insights + Impact Report

A Decade of Progress. A Future of Possibility.

The Cancer Research Institute (CRI)’s 2025 Cancer Immunotherapy Insights and Impact report offers a comprehensive, data-driven look at how immunotherapy has reshaped cancer treatment – from a promising frontier to a core pillar of care. With over 150 FDA approvals since 2011 and 17 new approvals in 2024 alone, the pace of innovation is accelerating and transforming lives.

This first-of-its-kind resource maps the rise of immune-based treatments across cancer types, therapeutic classes, and delivery methods. Whether you’re a patient, researcher, policymaker, or advocate, this report delivers essential insights into how far we’ve come and where the field is headed next.

What You’ll Discover

  • A decade-plus-long view of FDA immunotherapy approvals, by cancer type and therapy class
  • Historic, first-time approvals in 2024: the first tumor infiltrating lymphocyte (TIL) therapy, the first T-cell receptor (TCR)-engineered therapy for solid tumors, and the first IL-15 agonists
  • Real-world trends of how approved immunotherapies are being used across cancer types

Join our email list for updates on cancer immunotherapy research, events, and opportunities to get involved with the Cancer Research Institute. Sign up below and be a force for change in the fight against cancer.

Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

Father and son